Sulodexide in the treatment of early stages of COVID-19: A randomised controlled trial
Latest Information Update: 30 Jan 2022
At a glance
- Drugs Sulodexide (Primary)
- Indications COVID 2019 infections; Thrombosis
- Focus Therapeutic Use
- Acronyms ERSul
- 14 Dec 2021 Results (N=312) of ITT population presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 11 Mar 2021 New trial record
- 07 Mar 2021 Primary endpoint (decreasing the need for both hospital admission and supplemental oxygen treatment) has been met as per results published in the Thrombosis and Haemostasis.